+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase Not Applicable
All Ages
FEMALE
ID07521202

Evaluating Patient Coaching to Improve Abemaciclib Adherence in Women With HR-positive, HER2-negative Early Breast Cancer

Led by Institut fuer Frauengesundheit · Updated on 2026-11-04

257

Participants Needed

8

Research Sites

52 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the impact of standardized patient coaching on how consistently patients with hormone receptor-positive, HER2-negative early breast cancer take abemaciclib, a prescribed oral therapy. The study aims to find out if coaching based on a recognized teaching tool improves treatment adherence compared to routine care. Participants will provide information through several questionnaires to help answer this question. Participants receive standardized coaching based on the Multinational Association of Supportive Care in Cancer MASCC Oral Agent Teaching Tool MOATT. The coaching is designed to support patients while they take abemaciclib combined with endocrine therapy. The study follows patients for up to one year or until they stop taking abemaciclib permanently, whichever comes first. During the study, participants will complete questionnaires measuring their satisfaction with medicine information, medication adherence, and patient typology at 6 and 12 months after starting therapy. Researchers will monitor the time until patients discontinue abemaciclib as the main outcome. The study includes ongoing assessments to understand how coaching affects treatment persistence and patient experience over the year-long period.

CONDITIONS

Brief Title

IMPLEMENTING PATIENTS' COMPETENCE IN ORAL EBC THERAPY PERSISTENCE

Research Team

S

Sponsor's study office

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here